Supplementary Figures



Supplemental Figure 1. Burden testing scheme



Supplemental Figure 2. Homozygosity mapping of patients carrying homozygous

KPNA7 variants





Supplemental Figure 3. Structure, conservation, and expression pattern of

KPNA7

(A) The structure and protein domain architecture of KPNA7 and the location and conservation of the residues that were changed by the variants in *KPNA7*. IBB, importin

 β binding; ARM, armadillo. (**B**) The relative expression of *KPNA7* by Real-time qRT-

PCT in developing human oocytes, early embryos, and several somatic tissues.



Supplemental Figure 4. Localization of GFP-tagged wild-type and mutant KPNA7

constructs in HeLa cells



Supplemental Figure 5. Effect of variants on the binding ability and transport capacity of KPNA7

(A) In vitro nuclear transport assays of purified wild-type and missense mutant KPNA7 with the transport substrate GST-SV40TNLS-GFP when added Q69RanGTP. GTP fixed Ran affected transport ability of KPNA7. DNA was stained with DAPI. Scale bar = $30 \mu m$. (B) Quantitative analysis of KPNA7 transport capacity in (A). A total of 100 cells were counted. Data are shown as individual values with means \pm s.d. One-way ANOVA. (C) Ratio of average fluorescence intensity in the nucleus by comparing wild-

type group to mutant group. Functions of mutant KPNA7 were more sensitive to Q69LRanGTP. (**D**) Co-immunoprecipitation from HEK293T cells expressing FLAG-tagged wild-type or missense mutant KPNA7 and HA-tagged RSL1D1 with anti-FLAG beads. Missense alterations affect the interaction between KPNA7 and RSL1D1.



Supplemental Figure 6. Fertility of *Kpna7* knock-in and knockout female mice.

(A) Schematic diagram of *Kpna7* L222F knock-in and knockout. The red box indicates the knockout area. (B) Statistical analysis of the reproductive ability of wild-type and $Kpna7^{L222F/L222F}$ mice in the C57BL/6 background. n = 7. Data are shown as individual values with means \pm s.d. (C) In vitro embryonic development phenotype of wild-type

and $Kpna7^{L222F/L222F}$ mice. Scale bar = 100 µm. (**D**) Immunoblot of wild-type and missense mutant mouse KPNA7 proteins in HEK293T cells. Due to similar protein size of KPNA7 and GFP, blots were run in parallel. (**E**) RNA level of *Kpna7* in wild-type and *Kpna7*^{-/-} oocytes. *Kpna7* was completely knocked out in *Kpna7*^{-/-} oocytes. (**F**) Immunoblot of wild-type and *Kpna7*^{-/-} oocytes. (**G**) Statistical analysis of the reproductive ability of *Kpna7*^{-/-} mice in the C57BL/6 and ICR background. *n* = 10. Data are shown as individual values with means \pm s.d. (**H**) In vitro embryonic development phenotype of wild-type and *Kpna7*^{-/-} mice. Scale bar = 100 µm.









gRNA1

2

Mutant allele

4 5

4 5

3

G

Wild allele

Targeted allele





Exon1 Exon6





Supplemental Figure 7. Infertility of *Kpna2^{-/-}* females and fertility of *Kpna7^{-/-}* females.

(A) Schematic diagram of Kpna2 knockout mice. The red box indicates the knockout area. (B) Immunoblot of wild-type and $Kpna2^{-/-}$ oocytes. (C) The expression and localization of endogenous KPNA2 in 1-cell and 2-cell embryos from wild-type and $Kpna2^{-/-}$ females fertilized with wild-type sperms in vitro. Scale bar = 20 µm. (D) Localization of RSL1D1 at 3 h after injection of mClover3-RSL1D1 cRNA into zygotes from wild-type and $Kpna7^{-/-}$ females. Scale bar = 100 µm. (E) In vitro embryonic development phenotype after Rsl1d1 knockdown in mice and phenotypic rescue by mouse Rslldl cRNA injection into 2 PN zygotes. (F) Quantification of (E). Data are shown as individual values with means \pm s.d. n = 3 biological replicates. Unpaired twosided t-test. (G) Schematic diagram and Sanger sequencing confirmation of mice with an oocyte-specific knockout of *Rsl1d1*. The red box indicates the knockout area. (H) RNA level of *Rsl1d1* in oocytes and somatic tissues of wild-type and *Rsl1d1*^{OO-/-} mice. *Rsl1d1* was completely knocked out in *Rsl1d1*^{OO-/-} oocytes, while in somatic tissues, RNA level of Rsl1d1 did not change. (I) Incorporation of BrUTP to mark the synthesis of nascent transcripts in zygotes from wild-type and $Kpna7^{-/-}$ females. Scale bar = 100 μm. (J) Real-time qRT-PCR analyses of down-regulated genes in 2-cell embryos from $Kpna2^{-/-}$ females compared to embryos from $Kpna2^{+/-}$ females. Data are shown as mean \pm s.d.



Supplemental Figure 8. Phenotypic rescue by cRNA injection.

(A) Molecular rescue by cRNA injection of human *KPNA7* into *Kpna2^{-/-}* zygotes. After injection, the nuclear localization intensity of endogenous RSL1D1 in 2-cell embryos was stronger. (B) Fluorescence intensity of RSL1D1 in the nucleus of (A). Scale bar = 20 μ m. Data are shown as individual values with means ± s.d. *n* = 2 biological replicates. Unpaired two-sided *t*-test.

Supplementary Tables

Genomic Position on Chr 7 (bp)	cDNA Change	Protein Change	Variant Type	Inheritance ^c	Phenotype	ExAC ^b	GnomAD ^b	SIFT ^a	PPH2 ^a
98,790,671	c.C607T	p.L203F	missense	AR	embryo arrest	1.41E- 04	3.21E-04	D	Р
98,790,643	c.C635T	p.P212L	missense	AR	embryo arrest	4.75E- 05	6.02E-05	D	Р
98,792,723	c.C523A	p.Q175K	missense	AR	embryo arrest	NA	NA	D	Р
98,792,792	c.G454A	p.V152M	missense	AR	embryo arrest	NA	0.00003201	D	Р
98,775,650	c.1350_1356delGTGTCTT	p.C451*	frameshift	AR	embryo arrest	NA	NA	NA	NA

Supplemental Table 1. Overview of the KPNA7 variants

^aVariant assessment by SIFT and PolyPhen-2 (PPH2). D, damaging; P, probably damaging.

^bFrequency of corresponding variants in ExAC Browser and gnomAD. NA, not available.

^cAR, Autosomal recessive.

Family	Age (years)	Duration of infertility (years)	IVF & ICSI cycles	Total oocytes retrieved	MII oocytes with normal morphology	Normal fertilized oocytes	Normal cleaved embryos	Usable embryos at day 3	Usable blastocysts	Outcome of embryo transfer
			ICSI	20	20	18	18	0	0	/
			ICSI	10	8	6	6	0	0	/
1	39	12	ICSI	2	2	2	2	0	0	/
			ICSI	37	28	19	18	2	0	Failure
			ICSI	28	16	16	14	2	0	/
2	21	2	IVF	19	17	16	12	2	0	/
Z	31	3	ICSI	22	20	14	13	5	0	/
			IVF	5	2	2	2	0	/	/
			IVF	8	4	4	3	0	/	/
			IVF	10	8	8	8	2	0	Failure
			IVF	11	11	11	11	0	/	/
			IVF	1	1	1	1	0	/	/
3	37	7	IVF	17	16	16	15	1	/	/
			ICSI	10	8	8	6	0	/	/
			ICSI	10	9	8	7	2	0	Failure
			ICSI	10	6	6	5	0	/	/
			ICSI	15	10	10	9	2	/	/
			ICSI	22	15	15	11	4	0	Failure

Supplemental Table 2. Clinical characteristics of the patients with KPNA7 variants

1	20	0	ICSI	8	unknown	0	/	/	/	/
4	39	0	ICSI	12	6	4	4	0	/	/
			IVF	10	8	8	unknown	4	0	/
5	34	8	IVF	9	6	6	unknown	0	/	/
			IVF	11	8	unknown	unknown	0	/	/
			ICSI	13	unknown	4	4	0	/	/
6	44	15	ICSI	4	unknown	2	2	2	/	Failure
			ICSI	8	unknown	6	unknown	0	/	/
			ICSI	18	17	7	7	0	2	Failure
			ICSI	0	6	6	5	2	1	Embryo arrest at 12
7	35	8	ICSI	9	6	6	5	2	/	Embryo arrest at 12 weeks
7	35	8	ICSI ICSI	9 6	6 6	6 6	5 5	2 2	/	Embryo arrest at 12 weeks Failure
7	35	8	ICSI ICSI ICSI	9 6 12	6 6 7	6 6 7	5 5 7	2 2 1	/ / 0	Embryo arrest at 12 weeks Failure Failure
7	35	8	ICSI ICSI ICSI IVF	9 6 12 5	6 6 7 5	6 6 7 3	5 5 7 3	2 2 1 0	/ / 0 /	Embryo arrest at 12 weeks Failure Failure /
7	35 29	8	ICSI ICSI ICSI IVF ICSI	9 6 12 5 10	6 6 7 5 10	6 6 7 3 8	5 5 7 3 8	2 2 1 0 2	/ / 0 / /	Embryo arrest at 12 weeks Failure Failure / Failure
7 8 9	35 29 28	8 3 5	ICSI ICSI ICSI IVF ICSI IVF	9 6 12 5 10 20	6 6 7 5 10 20	6 6 7 3 8 14	5 5 7 3 8 14	2 2 1 0 2 2	/ / 0 / / / 0	Embryo arrest at 12 weeks Failure Failure / Failure /
7 8 9	35 29 28 36	8 3 5 7	ICSI ICSI ICSI IVF ICSI IVF IVF	9 6 12 5 10 20 7	6 6 7 5 10 20 unknown	6 6 7 3 8 14 unknown	5 5 7 3 8 14 unknown	2 2 1 0 2 2 0	/ / / / / 0 0	Embryo arrest at 12 weeks Failure Failure / Failure / /

/ refers to not applicable

Supplemental Table 3. Results of NCBI/Blastp

Description	Sequence ID
Transcription initiation factor TFIID subunit 1	XP_047298347.1
Transcription initiation factor TFIID subunit 1-like	NP_722516.1
KIAA2022	EAW98638.1
TAF4 RNA polymerase II	NP_003176.2
TBP-associated factor 1 isoform 2 variant	BAD92553.1
FACT complex subunit SPT16	NP_009123.1
Human TFIID bound to promoter DNA and TFIIA	6MZM_D
TBP-associated factor	AAC50901.1
Dystonia 3 (with Parkinsonism)	CAM98556.1
RSL1D1 protein	AAI07783.1
SURF6 protein	AAH03001.1
Unnamed protein product	BAG51440.1
Structure of the histone chaperone CIA/ASF1-double bromodomain complex linking histone modifications and site-specific histone eviction	3AAD_A
Myosin phosphatase Rho-interacting protein	XP_011522064.1
Rho-interacting protein 3	BAC78198.1
MPRIP protein	AAH09982.2
N-acetyltransferase ESCO1	NP_443143.2
Establishment of cohesion 1 homolog 1	AAH89426.1
Intermediate filament family orphan 2	NP_001129737.1
Probable RNA-binding protein 19	NP_001140170.1
Unnamed protein product	BAB14757.1

Splicing factor YJU2	NP_060544.2
Crystal Structure of Ubl123 with an EZH2 peptide	6P5L_D
Biorientation of chromosomes in cell division protein 1-like 1 isoform X1	XP_011512129.1
Zinc finger protein 40	NP_002105.3
Human immunodeficiency virus type I enhancer binding protein 1	EAW55310.1

			Incu	bation	
		24 h	48 h	72 h	108 h
	Fragmented/degenerated	0	0	5	23
	One-cell	2	2	1	1
WT	Two-cell	149	12	9	6
W I	Four-cell		137	0	0
	Morula			136	2
	Blastocyst				119
	Fragmented/degenerated	8	3	15	82
	One-cell	19	10	9	5
$V_{rate of} \gamma^{-/-}$	Two-cell	128	142	102	62
крпа2	Four-cell	1	1	30	7
	Morula			0	0
	Blastocyst				0

Supplemental Table 4. In vitro development of $Kpna2^{-/-}$ embryos (n = 6)

			Incu	bation	
		24 h	48 h	72 h	108 h
	Fragmented/degenerated	0	0	0	14
	One-cell	0	0	0	0
WT	Two-cell	72	4	0	0
W I	Four-cell		68	4	0
	Morula			68	0
	Blastocyst				58
	Fragmented/degenerated	2	9	19	23
	One-cell	20	15	8	7
D-11-1100-/-	Two-cell	40	37	33	30
RslId1	Four-cell		1	2	2
	Morula			0	0
	Blastocyst				0

Supplemental Table 5. In vitro development of $Rsl1d1^{OO-/-}$ embryos (n = 4)

Supplemental Table 6. Primers used for plasmid construction and real-time PCR

Primer name	Sequence (5'-3')	Application
PCMV6-Flag-KPNA7-F	GAGGCGATCGCATGGATTACAAGGATGACGACGATAAGCCGACCTT	
	AGATGCTCCAGAA	
PCMV6-Flag-KPNA7-R	GCGACGCGTCTATTTTTTGCTAAGCATTCATAATCTATAAATTCATA	
	ATCTTGGTCT	
PCMV6-Flag-mKpna7-F	GAGGCGATCGCATGGATTACAAGGATGACGACGATAAGGCTACCTC	
	AAAGGCTCCCAAA	
PCMV6-Flag-mKpna7-R	GCGACGCGTTCACACTCTCAGCCCAGGCCCGGGC	
hKPNA7-203-F	TTCCTAGCCTTGATTTCACCCACCCTGCCG	
hKPNA7-203-R	ATGTGGGATGGCATTGCTTGTGATGACGTT	
hKPNA7-212-F	TGATCACATTTCTGCGGAACATCACGTGGA	DCD for plagmid
hKPNA7-212-R	GCAGGGTGGGTGAAATCAAGGCTAGGAGAT	PCR for plasmid
hKPNA7-175F	AAGGCAGTGTGGGCTCTTGGTAA	construction
hKPNA7-175-R	TTCACACAGCCACGTTGGAGG	
hKPNA7-152-F	ATGGTAGAAGGGGGGGGGCCATCC	
hKPNA7-152-R	GGCACGAGTCTGCTCCGAAG	
hKPNA7-451-F	CTGATAGAAGAACTTGGTGGGATCGAT	
hKPNA7-451-R	AGGTTTTCCTTCAGACCGTTTCT	
mKpna7-222-F	TTCATCAACCTTATTTCAAAAGGCATACCAATC	
mKpna7-222-R	GTGTGGGATGGCATTATTGGAGATGAC	
mKpna7-231-F	TAATCACATTTCTTCGGAACATCTCATGGAC	
mKpna7-231-R	GTATGCCTTTTGAAATAAGGTTGATCAGGTGTGG	

mKpna7-173-F	AAGGCAGTGTGGGGCCCTTGGGAATA	
mKpna7-173-R	CTCAGACACTGTCAGGTGTGGGGGAA	
mKpna7-150-F	ATGGTGAAAGAGGGTGCCATTCAG	
mKpna7-150-R	AGCTCGGGTCTGCTCTGAAG	
PCMV6-hKPNA2-Ha-F	GAGGCGATCGCATGTCCACCAACGAGAATGCTAAT	
PCMV6-hKPNA2-Ha-R	GCGACGCGTAAAGTTAAAGGTCCCAGGAGCCCCAT	
PCMV6-mKpna2-Ha-F	GAGGCGATCGCATGTCCACGAACGAGAATGCTAACTTACC	
PCMV6-mKpna2-Ha-R	GCGACGCGTGAAGTTAAAGGTCCCAGGAGCTCCAT	
pGEX4T-mRSL1D1-GFP-F	CGCGTGGATCCCCGGAATTCATGGAGGATTCGGCCTCGGC	
RSL1D1-GFP-R	AGTTCTTCTCCTTTACTGGTCGACTGGGGTACTTTGGG	
RSL1D1-GFP-F	CCCCAGTCGACCAGTAAAGGAGAAGAACTTTTCACTGGAGTTG	
pGEX4T-mRSL1D1-GFP-R	GTCAGTCACGATGCGGCCGCCTATTTGTATAGTTCATCCATGCCATG	
	TGTAATCCC	
PCMV6-hRSL1D1-Ha-F	AGATCTGCCGCCGCGATCGCATGGAGGATTCGGCCTCGG	
PCMV6-hRSL1D1-Ha-R	TCGAGCGGCCGCGTACGCGTGGTCGACTGGGGTACTTTGGG	
PCMV6-mRSL1D1-Ha-F	GATCTGCCGCCGCGATCGCATGAAGGGCTCTGCGTCCG	
PCMV6-mRSL1D1-Ha-R	TCGAGCGGCCGCGTACGCGTGTTTGAGTGGGCCGCCTTG	
mRSL1D1-sysnmut-F	GTCTGCTTATTCACAAAAGATGAATTCGATTCACC	
mRSL1D1-sysnmut-R	GTCGGATGATTCGGAGAGAATGCTATGAGGCAAAG	
pCR3.1-mClover-mRSL1D1-F	CTTCAGATCTGGTTACGCGTATGAAGGGCTCTGCGTCCGAATC	
pCR3.1-mClover-mRSD1-R	TTCTGGATATACCACAGCGATCGCCTAGTTTGAGTGGGCCGCCTTG	
KPNA7-mRT-F	GACATCATTTCTTATCTCCTCCAG	For real-time
KPNA7-mRT-R	GCAAACTGTCACCATCTCCATC	quantitative
KPNA6-mRT-F	CACTGCTGGCAACAGGGCTCAA	PCRs

KPNA6-mRT-R	GCAGCCCAGTGATACCAGGTAC
KPNA4-mRT-F	CAATCTCATAGAAGAATGTGGTG
KPNA4-mRT-R	CTCTGTTGGTACATTGGTCGAT
KPNA3-mRT-F	TGAGATCATAGAAGAGTGTGGAG
KPNA3-mRT-R	TGAAGGTTGGCTGTTGGGTC
KPNA2-mRT-F	TGATGCTACTTCTCCGCTACAG
KPNA2-mRT-R	GGATGATGTTGTCTATAGGAGG
KPNA1-mRT-F	ACAGCTGGAAATAGGGCACAGA
KPNA1-mRT-R	GATACAACCCAGTTCTACTAGGTAC
KPNA7-hRT-F	GTGATGGCCCAGAGTTCAGAGATAA
KPNA7-hRT-R	CATCCGAGAGAACCTCACTGTCCTG
KPNA6-hRT-F	GCATTCAGCTCCGGAAGCAGAA
KPNA6-hRT-R	GTGTGGTTGCTAACTGCAGGT
KPNA5-hRT-F	TAGTTCCACTGTACCCATTCCAGAG
KPNA5-hRT-R	TCTCTGTACAACTCCTGGTTTCTGT
KPNA4-hRT-F	ACTATGAGAAGACAACGAAATGAAGTTG
KPNA4-hRT-R	TAGCAGCTTGAACTGCACTTAATTG
KPNA3-hRT-F	TGAAGTGACAGTGGAACTGCGGAAG
KPNA3-hRT-R	CTTGCTGCCTGGACAGCACTCAATT
KPNA2-hRT-F	GAAATGAGGCGTCGCAGAATAGAGG
KPNA2-hRT-R	CTGGCAGCTTGAGTAGCTTGGAG
KPNA1-hRT-F	CAGATTAGTAACATGGAGATGGCACCA
KPNA1-hRT-R	CCACAAACCTGGCCACTACTCCT
GAPDH-hRT-F	GGAGCGAGATCCCTCCAAAAT

GAPDH-hRT-R	GGCTGTTGTCATACTTCTCATGG
ACTB-hRT-F	ATGATGATATCGCCGCGCTC
ACTB-hRT-R	AATCCTTCTGACCCATGCCC
Kpna2-mRT-F	TGATGCTACTTCTCCGCTACAG
Kpna2-mRT-R	GGATGATGTTGTCTATAGGAGG
Kpna7-mRT-F	GACATCATTTCTTATCTCCTCCAG
Kpna7-mRT-R	GCAAACTGTCACCATCTCCATC
Actb-mRT-F	CAGCTTCTTTGCAGCTCCTT
Actb-mRT-R	AGTCCTTCTGACCCATTCCCA
Bclaf1-mRT-F	ATGGCACCTGTTCCTCTTGACG
Bclaf1-mRT-R	GAGGCAGCTTAATGTGGTCAAAG
Crcp-mRT-F	CAAAGAGCAGCGGAAGGAGAGT
Crcp-mRT-R	GACAATCGCTGGACTCTGGTTC
Polr3k-mRT-F	AGAAGTGGACGACGTGCTTGGT
Polr3k-mRT-R	AGAAGGTGGTCATTGGCTCGTC
Znrd1-mRT-F	GTCTGTGGATGAGGGACCTGAA
Znrd1-mRT-R	AGACCGTCTGTCCTTCATCAGC
Zmpste24-mRT-F	CTACTCAGAGGTGGAAGGCACT
Zmpste24-mRT-R	ACAGCAGGAACACCAATGACTGA
Xrn2-mRT-F	CAGTTTGGACACGAGGTCAAGG
Xrn2-mRT-R	ACTCTCGAAGGACATTCAGCCG
Gtf2f2-mRT-F	ACAGTGTTTACGGAGAGCTCCTCAG
Gtf2f2-mRT-R	CAGCTGTTGTGAGAGCCTTACAGGT
Wdr61-mRT-F	GCTCCTTGTCACGGCTTCAGAT

Wdr61-mRT-R	GTGTCATCAGGACAGAACGCAAC
Dhx36-mRT-F	GTCTTTCTACCAGGCTGGGACA
Dhx36-mRT-R	GTGTCTGGTTGACGGTAGGCAT
Aars-mRT-F	CCAATCAGACTCCAGTGGTAGC
Aars-mRT-R	GCTCCGCATAGAAACAGGTCTTGT

Abbreviations: F forward, R reverse